Loading...
Cynata Therapeutics Limited
CYP.AX•ASX
Healthcare
Biotechnology
A$0.17
A$0.02(9.68%)
Cynata Therapeutics Limited (CYP.AX) Financial Performance & Income Statement Overview
Review Cynata Therapeutics Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
39.98%
↑ 39.98%
Operating Income Growth
46.76%
↑ 46.76%
Net Income Growth
31.75%
↑ 31.75%
Operating Cash Flow Growth
30.26%
↑ 30.26%
Operating Margin
-900.42%
↓ 900.42%
Gross Margin
91.93%
↑ 91.93%
Net Profit Margin
-508.80%
↓ 508.80%
ROE
-94.67%
↓ 94.67%
ROIC
-136.40%
↓ 136.40%
Cynata Therapeutics Limited (CYP.AX) Income Statement & Financial Overview
Review Cynata Therapeutics Limited's (CYP.AX) income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $1.97M | -$230069.00 | $2.55M | -$146694.00 |
| Cost of Revenue | $0.00 | $140366.00 | $140366.00 | $139982.00 |
| Gross Profit | $1.97M | -$370435.00 | $2.41M | -$286676.00 |
| Gross Profit Ratio | $1.00 | $1.61 | $0.94 | $1.95 |
| R&D Expenses | $0.00 | $8.96M | $0.00 | $12.67M |
| SG&A Expenses | $4.55M | $3.89M | $6.95M | $9.17M |
| Operating Expenses | $4.55M | $12.85M | $6.95M | $9.17M |
| Total Costs & Expenses | $4.55M | $12.85M | $7.09M | $9.31M |
| Interest Income | $0.00 | $187641.00 | $230069.00 | $206175.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $136685.00 | $140366.00 | $140366.00 | $139982.00 |
| EBITDA | -$3.51M | -$5.55M | -$6.72M | -$8.96M |
| EBITDA Ratio | -$1.78 | $24.12 | -$2.64 | $62.52 |
| Operating Income | -$2.58M | -$13.08M | -$7.09M | -$9.31M |
| Operating Income Ratio | -$1.31 | $56.87 | -$2.78 | $63.47 |
| Other Income/Expenses (Net) | -$1.07M | $7.88M | $230069.00 | $7.64M |
| Income Before Tax | -$3.65M | -$5.20M | -$6.86M | -$9.10M |
| Income Before Tax Ratio | -$1.85 | $22.62 | -$2.69 | $62.06 |
| Income Tax Expense | $0.00 | $0.00 | -$2.32M | -$2.00 |
| Net Income | -$3.65M | -$5.20M | -$4.54M | -$9.10M |
| Net Income Ratio | -$1.85 | $22.62 | -$1.78 | $62.06 |
| EPS | -$0.02 | -$0.03 | -$0.03 | -$0.06 |
| Diluted EPS | -$0.02 | -$0.03 | -$0.03 | -$0.06 |
| Weighted Avg Shares Outstanding | $184.33M | $179.78M | $179.63M | $146.14M |
| Weighted Avg Shares Outstanding (Diluted) | $184.33M | $179.77M | $179.63M | $146.14M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan